enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Allergan plc Stock Becomes a Buy as It Bottoms Out - AOL

    www.aol.com/allergan-plc-stock-becomes-buy...

    Shareholders are not very pleased with Allergan plc (NYSE:AGN) after it reported first-quarter results for 2018. Allergan stock is worth a second look. Allergan’s sale of Teva stock is ...

  3. Allergan - Wikipedia

    en.wikipedia.org/wiki/Allergan

    Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.

  4. Allergan, Inc. - Wikipedia

    en.wikipedia.org/wiki/Allergan,_Inc.

    Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. [ 2 ]

  5. Actavis - Wikipedia

    en.wikipedia.org/wiki/Actavis

    Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial ...

  6. Top Stock Reports for Booking Holdings, Allergan & Honda ...

    www.aol.com/news/top-stock-reports-booking...

    For premium support please call: 800-290-4726 more ways to reach us

  7. Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More - AOL

    www.aol.com/news/drug-biotech-stocks-nov-5...

    Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

  8. List of largest pharmaceutical mergers and acquisitions

    en.wikipedia.org/wiki/List_of_largest...

    Allergan, Inc: 53.3 69 Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals: Allergan, Inc: 49.4 64

  9. For premium support please call: 800-290-4726 more ways to reach us